Published : Aug-2021
No. of Pages : 133
1 Respiratory Syncytial Virus: Executive Summary
1.1 Strong Growth Projected for the RSV Market from 2020 to 2030
1.2 The Market for RSV Prophylaxis Is Untapped and Highly Competitive
1.3 Remaining Opportunities for Current and Future Players
1.4 Future RSV Management Strategies Will Include Multiple Products
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
4 Epidemiology
4.1 Disease Background
4.1.1 Risk Factors and Comorbidities
4.2 Global and Historical Trends
4.3 Forecast Methodology
4.3.1 Sources
4.3.2 Forecast Assumptions and Methods
4.4 Epidemiological Forecast for RSV Prophylactic Population (2020-2030)
4.4.1 Number of Preterm Births by Gestational Age
4.4.2 Preterm Infants with CLD
4.4.3 Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease
4.4.4 Diagnosed Prevalent Cases of DMD
4.4.5 Number of Diagnosed Prevalent Cases of SMA
4.4.6 Number of Third-Trimester Pregnant Women
4.4.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions
4.5 Discussion
4.5.1 Epidemiological Forecast Insight
4.5.2 COVID-19 Impact
4.5.3 Limitations of the Analysis
4.5.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Passive Prophylaxis
7.3 Prophylactic Vaccines
7.4 Effective Therapeutic Antivirals
7.5 Increased Diagnostic Testing
7.6 Increased Research and Awareness of Long-Term Sequelae
8 R&D Strategies
8.1 Overview
8.1.1 Leveraging Novel Vaccine Technologies and Strategies
8.2 Clinical Trials Design
8.2.1 Clinical Trial Designs for RSV Vaccines for Maternal Immunization
8.2.2 Clinical Trials Designs for RSV Prophylactics for Pediatric Patients
8.2.3 Clinical Trials Design of Pipeline Prophylactics for Adult Immunization
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 Australia
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers
13 Appendix
List of Tables
Table 1: Respiratory Syncytial Virus: Key Metrics in the 8MM
Table 2: Risk Factors for Severe RSV
Table 3: Leading Treatments for RSV, 2021
Table 4: Treatment Guidelines for RSV
Table 5: Clinical Trial Designs for RSV Vaccines for Maternal Immunization
Table 6: Clinical Trial Designs for RSV Prophylactics for Pediatric Patients
Table 7: Clinical Trial Designs for RSV Prophylactics for Adult Patients
Table 8: Innovative Early-Stage Approaches for RSV, 2021
Table 9: Drugs in Early-Stage Development for RSV, 2021
Table 10: RSV Prophylactics Market - Global Drivers and Barriers, 2020-2030
Table 11: Key Events Impacting Sales for RSV Prophylactics in the US, 2020-2030
Table 12: RSV Prophylactics Market - Drivers and Barriers in the US, 2020-2030
Table 13: Key Events Impacting Sales for RSV Prophylactics in the 5EU, 2020-2030
Table 14: RSV Prophylactics Market - Drivers and Barriers in the 5EU, 2020-2030
Table 15: Key Events Impacting Sales for RSV Prophylactics in Japan, 2020-2030
Table 16: RSV Prophylactics Market - Drivers and Barriers in Japan, 2020-2030
Table 17: Key Events Impacting Sales for RSV Prophylactics in Australia, 2020-2030
Table 18: RSV Prophylactics Market - Drivers and Barriers in Australia, 2020-2030
Table 19: RSV Prophylaxis Launch Dates
Table 20: RSV Prophylaxis Patent Expiration Dates
Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Respiratory Syncytial Virus in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Respiratory Syncytial Virus During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of RSV During the Forecast Period
Figure 4: Structure of Human RSV Virion
Figure 5: RSV Life Cycle
Figure 6: 8MM, Rate of Preterm Births (per 1,000 Live Births), 2020-2030
Figure 7: 8MM, Percentage of Adults Living in Long-Term Care, Ages ?55 Years, 2020-2030
Figure 8: 8MM, Sources Used to Forecast the Number of Preterm Births
Figure 9: 8MM, Sources Used to Forecast the Number of Preterm Births with CLD
Figure 10: 8MM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease
Figure 11: 8MM, Sources Used to Forecast the Number of Live Births with Congenital Lung Disease
Figure 12: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of DMD
Figure 13: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA
Figure 14: 8MM, Sources Used to Forecast the Number of Third-Trimester Pregnancies
Figure 15: 8MM, Sources Used to Forecast the Number of Adults Living in Long-Term Care
Figure 16: 8MM, Number of Preterm Births by Gestational Age, N, 2020
Figure 17: 8MM, Number of Preterm Infants with CLD, N, 0-Year, 2020-2030
Figure 18: 8MM, Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease, 2020, 0-Year
Figure 19: 8MM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2020-2030
Figure 20: 8MM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2020-2030
Figure 21: 8MM, Number of Third-Trimester Pregnant Women, N, 2020-2030
Figure 22: 8MM, Number of Adults Living in Care Institutions, Ages ?55 Years, N, 2020-2030
Figure 23: Unmet Needs and Opportunities in RSV
Figure 24: Overview of the Development Pipeline in RSV
Figure 25: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for RSV in the 8MM During the Forecast Period
Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of RSV During the Forecast Period
Figure 27: Clinical and Commercial Scores of Key Pipeline Prophylactics Against the SOC, Synagis
Figure 28: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Synagis
Figure 29: Analysis of the Company Portfolio Gap in RSV Prophylaxis During the Forecast Period
Figure 30: Global (8MM) Sales Forecast by Country for RSV Prophylactics in 2020 and 2030
Figure 31: Sales Forecast by Class for Pediatric and Adult RSV Prophylactics in the US in 2030
Figure 32: Sales Forecast by Class for RSV Prophylactics in the 5EU in 2020 and 2030
Figure 33: Sales Forecast by Class for Pediatric and Adult RSV Prophylactics in Japan in 2030
Figure 34: Sales Forecast by Class for Pediatric and Adult RSV Prophylactics in Australia in 2030
